Prediction Case File
YouTubeTracking Live

Nvidia – Novo Nordisk – Nike: Großes Kaufsignal!

1 extracted signal · 0 resolved · 1 still active

Erichsen profile imageErichsenIndependent analyst profile
Source published
18 Nov 2026, 17:00 UTC
Recorded by Tahlil Plus
18 Nov 2026, 18:59 UTC
Video preview for Nvidia – Novo Nordisk – Nike: Großes Kaufsignal!
Source overview

AI-generated source summary

The speaker analyzes three major stocks—Novo Nordisk, Nvidia, and Nike—using long-term and short-term technical analysis, moving averages, and retracement levels. While Novo Nordisk and Nike show potential bottom-building setups near critical support levels after significant corrections, Nvidia remains under pressure with a cautious near-term outlook despite strong historical growth.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Erichsen

Platform-wide history, separate from this source evaluation.

Reliability
66.9
Tracked signals
13
Historical success
75.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail